Argenta Signs Integrated Services Agreement with Pulmagen Therapeutics

Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects.

Under the terms of the agreement, Argenta will be eligible to receive up to £6 million (€7 million) in fee-for-service payments over two years, with the possibility to extend. Building on its excellent reputation in respiratory diseases, Argenta will perform chemistry, biology, ADMET/PK and pharmacology services to bring two respiratory projects to pre-clinical status.

“We are pleased that Pulmagen has come to Argenta for two projects of such substantial scope. These projects will make a strong contribution to the service operations’ performance in 2011,” said Dr Chris Newton, SVP Services of Galapagos. “Today’s agreement also demonstrates how well positioned Argenta is to perform longer term, integrated projects for its clients.”

The deal with Argenta is part of a discovery and development collaboration that Pulmagen has established with Chiesi Farmaceutici S.p.A., a private Italian Group, with focus in respiratory diseases. The purpose of the discovery programs is to identify new compounds with anti-inflammatory potential to be developed for respiratory conditions characterised by a high unmet medical need such as COPD and cystic fibrosis. The terms of the collaboration between Pulmagen and Chiesi are not disclosed.

Pulmagen Therapeutics

Pulmagen Therapeutics
Respiratory drug development


DownloadFull Press Release

Latest News

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.